Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 165 results found since Jan 2013.

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Green Tea Consumption Improves Prognosis for Stroke, MI Survivors
THURSDAY, Feb. 4, 2021 -- For stroke and myocardial infarction (MI) survivors, green tea consumption is associated with improved prognosis, according to a study published online Feb. 4 in Stroke. Masayuki Teramoto, M.D., from the Osaka University...
Source: Drugs.com - Pharma News - February 4, 2021 Category: Pharmaceuticals Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. Presidential Election Linked To More Heart Attacks And Strokes, Study Finds
Heart attack and stroke hospitalisations doubled in the two days immediately after the 2016 presidential election, according to a new study.
Source: Forbes.com Healthcare News - October 12, 2020 Category: Pharmaceuticals Authors: Misha Gajewski, Contributor Tags: Healthcare /healthcare Innovation /innovation Money /money Election 2020 /election-2020 Source Type: news

Nearly Half of Hispanics, Blacks Scared to Go to Hospital During COVID-19
WEDNESDAY, July 29, 2020 -- Hispanics and blacks are most likely to stay home if experiencing medical emergencies, like a heart attack or stroke, to avoid the risk of contracting COVID-19 at the hospital, according to a poll released by the American...
Source: Drugs.com - Pharma News - July 29, 2020 Category: Pharmaceuticals Source Type: news

ED Use Down for MI, Stroke, Hyperglycemic Crisis in COVID-19
WEDNESDAY, June 24, 2020 -- Following declaration of the COVID-19 pandemic as a national emergency, there was a decrease in visits to the emergency department for myocardial infarction (MI), stroke, and hyperglycemic crisis, according to research...
Source: Drugs.com - Pharma News - June 24, 2020 Category: Pharmaceuticals Source Type: news

Heart Disease Risk Up for First-Time Mothers With Preeclampsia
MONDAY, April 6, 2020 -- First-time mothers with preeclampsia are at a higher risk for adverse cardiovascular outcomes, including myocardial infarction, stroke, and cardiovascular death, according to a study recently published in the Journal of...
Source: Drugs.com - Pharma News - April 6, 2020 Category: Pharmaceuticals Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

FDA Panel: Expand Use of Fish Oil Drug Vascepa
FRIDAY, Nov. 15, 2019 -- Approved use of the prescription-strength fish oil drug Vascepa should be widened to include more patients at risk for heart attack and stroke, a U.S. Food and Drug Administration advisory panel recommended Thursday. Vascepa...
Source: Drugs.com - Pharma News - November 15, 2019 Category: Pharmaceuticals Source Type: news

How Much Dog Do You Need For Optimum Health?
Two new studies show that owning a dog reduces your risk of dying. The benefits are even greater for people who recently had a heart attack or stroke. So how many dogs should you get, and how big should they be?
Source: Forbes.com Healthcare News - October 28, 2019 Category: Pharmaceuticals Authors: Steven Salzberg, Contributor Source Type: news

Day Or Night —When Is The Best Time To Take Your Blood Pressure Medicine?
The time of day when you take your blood pressure medication could influence your risk for complications such as heart attack and stroke, which is ultimately linked to how well you manage your blood pressure.
Source: Forbes.com Healthcare News - October 24, 2019 Category: Pharmaceuticals Authors: Robert Glatter, MD, Contributor Source Type: news